Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Zentalis Reports 15.9-Month Median Overall Survival With Azenosertib in Cyclin E1-Positive Ovarian Cancer Trial

By Public Technologies
  • Zentalis Pharmaceuticals presented interim DENALI Part 1b results for investigational ovarian cancer treatment azenosertib at the ESMO Congress 2026.
  • Patients with Cyclin E1-positive platinum-resistant ovarian cancer had longer median overall survival than those with Cyclin E1-negative tumors.
  • The findings support Cyclin E1 protein expression as a patient-selection biomarker for azenosertib.
  • Safety remained consistent with prior reports, with treatment-related adverse events prompting dose changes or discontinuation in some patients.
  • Azenosertib remains under development in the registration-intended DENALI Part 2 study and ASPENOVA Phase 3 confirmatory trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610231015PRIMZONEFULLFEED9851795) on October 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.